Olema Oncology Reports Fourth Quarter and Full-Year 2023 : vimarsana.com

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4...

Related Keywords

Massachusetts , United States , San Francisco , California , Spain , Madrid , Cambridge , Cambridgeshire , United Kingdom , Berlin , Germany , Geoffrey Mogilner , Seanp Bohen , Nasdaq , Breast Cancer Annual Congress , Novartis Institutes For Biomedical Research Inc , Silicon Valley Bank , Securities Exchange , Novartis , Drug Administration , Olema Pharmaceuticals Inc , European Society For Medical Oncology , Exchange Commission , Cancer Annual Congress , Chief Executive Officer , Cancer Annual , Antonio Breast Cancer Symposium , European Society , Medical Oncology , Novartis Institutes , Biomedical Research , Investigational New Drug , Fast Track , Securities Act , Securities Exchange Act , Annual Report , Consolidated Statements , Months Ended December , Media Contact , Vice President , Investor Relations , Nasdaq Olma , Lema Pharmaceuticals , Nc , Iotech , Arnings , Lma , Reast Cancer ,